News
The Assault class is the frontline segment. They are responsible for pushing through enemy defenses using some of the most ...
Razer is offering players a chance to get their hands on Battlefield 6 early access codes. The official Razer social pages ...
Aligos Therapeutics (ALGS) delivered earnings and revenue surprises of +34.89% and -3.50%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?
12h
TipRanks on MSNAligos Therapeutics reports Q2 EPS ($1.53), consensus ($2.54)Reports Q2 revenue $965,000, consensus $433,330. “Initiation of the Phase 2 B-SUPREME study of ALG-000184 is well underway with regulatory ...
Aligos Therapeutics, Inc. (Nasdaq: ALGS, “Aligos”), a clinical stage biotechnology company focused on improving patient outcomes through best-in-class therapies for liver and viral diseases, today ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results